CLINICAL TRIALS PROFILE FOR ARRANON
✉ Email this page to a colleague
All Clinical Trials for ARRANON
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00002970 ↗ | 506U78 in Treating Patients With Refractory Hematologic Cancer | Completed | Children's Cancer Group | Phase 2 | 1997-06-01 | Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
NCT00002970 ↗ | 506U78 in Treating Patients With Refractory Hematologic Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-06-01 | Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
NCT00005080 ↗ | 506U78 in Treating Patients With Lymphoma | Completed | National Cancer Institute (NCI) | Phase 2 | 2000-05-01 | Phase II trial to study the effectiveness of 506U78 in treating patients who have lymphoma that has not been treated previously or that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die |
NCT00005950 ↗ | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | Terminated | National Cancer Institute (NCI) | Phase 2 | 2000-04-01 | Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die |
NCT00005982 ↗ | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | Terminated | National Cancer Institute (NCI) | Phase 2 | 2000-04-01 | Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma |
NCT00016302 ↗ | Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Completed | National Cancer Institute (NCI) | N/A | 2001-04-01 | Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. This phase II trial is studying several different combination chemotherapy regimens to see how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARRANON
Condition Name
Condition Name for ARRANON | |
Intervention | Trials |
Recurrent Adult T-cell Leukemia/Lymphoma | 2 |
Angioimmunoblastic T-cell Lymphoma | 2 |
T Acute Lymphoblastic Leukemia | 2 |
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | 2 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for ARRANON
Trials by Country
Clinical Trial Progress for ARRANON
Clinical Trial Phase
Clinical Trial Sponsors for ARRANON
Sponsor Name